眼科領域におけるgatifloxacinの臨床的検討

• 吉野 啓

  杏林大学医学部眼科学教室

• 藤原 隆明

  杏林大学医学部眼科学教室

• 坪井 實

  エヌ・エスクリニック

書誌事項

タイトル別名

• Clinical efficacy of gatifloxacin in external eye diseases and its penetration into human tears
• 涙液中への移行性の検討ならびに臨床効果の評価

抄録

Gatifloxacin (GFLX) is a newly developed fluoroquinolone derivative for oral use. We examined the clinical efficacy and safety of GFLX in 6 patients with eye infections. The following cases were studied: 3 cases of meibomitis, and 1 each of blepharitis, hordeolum, and conjunctivitis. GFLX was administrated b. i. d. at a dose of 200mg for 3 to 8 days. Its clinical efficacy was excellent in 4, case good in 1, and fair in 1. No side effects and no clinical abnormal findings were observed. The drug was judged useful in 5 cases and fairly useful in 1.<BR>After a single oral administration of 200mg of GFLX in 9 fasting healthy volunteers, GFLX levels in both tear fluid and serum were determined. The peak level of GFLX in tear fluid reached 1.22±0.90 μg/mL at 0.5 h after administration and the tear/serum ratio was 0.85±0.34 at the same time.

収録刊行物

• 日本化学療法学会雑誌

  日本化学療法学会雑誌 47 (Supplement2), 253-259, 1999

  公益社団法人 日本化学療法学会

キーワード

• AM-1155
• ニューキノロン薬
• 眼科領域感染症
• 涙液中移行

詳細情報

• CRID: 1390001206289657728
• NII論文ID: 10008029250
• NII論文ID: 130004297957
• NII書誌ID: AN10472127
• DOI: 10.11250/chemotherapy1995.47.supplement2_253
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2000046854
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可